Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

IGI Laboratories, Inc. : Announces Change to Its Executive Management Team

share with twitter share with LinkedIn share with facebook
share via e-mail
07/30/2012 | 03:10pm CET

Jason Grenfell-Gardner appointed as CEO of IGI Laboratories, Inc.

IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based pharmaceutical company, today announced that Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of IGI Laboratories, Inc. effective July 30, 2012.

Ms. Joyce Erony, Chairman of the Company, commented, "On behalf of the Board of Directors, I would like to express my gratitude for the dedication and leadership provided by Charlie Moore during his tenure at IGI as President and Chief Executive Officer. I would also like to take this opportunity to congratulate Jason whose comprehensive experience in the pharmaceutical market and the commercialization of products makes Jason the appropriate leader to establish the IGI brand and portfolio of generic topical prescription drug products in the marketplace."

Jason Grenfell-Gardner brings significant experience in the pharmaceutical industry, with a particular focus on generics. Most recently, Jason was the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals, the US Subsidiary of Hikma Pharmaceuticals. Jason has served in that role since 2008. Jason was an integral part of the senior management team which grew the business from just over $100 million in 2008 to over $300 million in 2011. He solidified West-Ward's presence in the sterile injectable space through the acquisition of Baxter International, Inc.'s multisource injectable business in 2011. He originally joined Hikma Pharmaceuticals to lead its initial public offering in 2004, and later headed their business development efforts.

Prior to 2004, Jason gained a number of years of investment banking experience in Central and Eastern Europe with Trigon Capital, and served as Chairman of the Board of Sanitas Pharmaceuticals. Jason has an MA in Economics from the University of St. Andrews in Scotland, and an MBA from INSEAD, where he studied in both France and Singapore.

About IGI Laboratories, Inc.

IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets.

IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.'s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

IGI Laboratories, Inc.
Jenniffer Collins, 856-697-4379

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on IGI LABORIGI
12:31pTELIGENT INC : Blog Exposure - FDA Approved Teligent’s Halobetasol Propionate Oi..
03/21TELIGENT : Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
03/21TELIGENT : Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%
03/16TELIGENT : Announces Fourth Quarter and Year End 2017 Results
03/15TELIGENT : reports 4Q loss
03/15TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
03/15TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
03/15Teligent, Inc. Announces Fourth Quarter and Year End 2017 Results
03/15TELIGENT, INC. : Non-Reliance on Previous Financials, Audits or Interim Review (..
More news
Financials ($)
Sales 2018 76,2 M
EBIT 2018 -2,15 M
Net income 2018 -13,9 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 3,18x
Capi. / Sales 2019 1,78x
Capitalization 171 M
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,11 $
Spread / Average Target 59%
EPS Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Damian Finio Chief Financial Officer
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.11%351 935
PFIZER0.14%215 910
NOVARTIS-7.31%210 505
ROCHE HOLDING LTD.-12.21%198 996
MERCK AND COMPANY-3.82%147 455